<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>From 1985 to 2004, 49 patients with advanced <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) (&gt; or =5% blasts) or <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) transformed from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> underwent T cell depleted bone marrow or peripheral blood hematopoietic stem cell transplantation (HSCT) from HLA-identical siblings following conditioning with a myeloablative regimen that included total body irradiation (44 patients) or <z:chebi fb="0" ids="28901">busulfan</z:chebi> (5 patients) </plain></SENT>
<SENT sid="1" pm="."><plain>Thirty-six patients received chemotherapy (3 low dose and 33 induction doses) before conditioning, and 13 patients did not receive any chemotherapy </plain></SENT>
<SENT sid="2" pm="."><plain>Prior to transplantation, 22 of the 36 treated patients were in hematologic remission; 4 were in a second refractory cytopenia phase (26 responders); 8 had failed to achieve remission; and 2 of the responders had progression or relapse of their <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (10 failures) </plain></SENT>
<SENT sid="3" pm="."><plain>No post-transplantation pharmacologic prophylaxis for <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> (GVHD) was given </plain></SENT>
<SENT sid="4" pm="."><plain>The median age was 48 yrs (range 13-61) </plain></SENT>
<SENT sid="5" pm="."><plain>Forty-five of the 49 patients engrafted; 2 had primary graft failure; and 2 died before engraftment </plain></SENT>
<SENT sid="6" pm="."><plain>Only 3 patients developed <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD (aGVHD) (grades I and III) and 1 <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD (cGVHD) </plain></SENT>
<SENT sid="7" pm="."><plain>At 3 yrs post-transplantation, the overall survival (OS) was 54% in the responders; 31% in the untreated group; and 0% in the failure group (P=.0004) </plain></SENT>
<SENT sid="8" pm="."><plain>The disease free survival (DFS) was 50%, 15% and 0% in each group respectively (P=.0008) </plain></SENT>
<SENT sid="9" pm="."><plain>In multivariate analysis, disease status before cytoreduction remained highly correlated with DFS (P&lt;.001) </plain></SENT>
<SENT sid="10" pm="."><plain>The cumulative incidence (CI) of relapse at 2-yrs post-transplantation for the responders was 23%; for the untreated group was 38%; and for the failures was 50% </plain></SENT>
<SENT sid="11" pm="."><plain>The CI of non-relapse mortality at 2-yrs post-transplantation, for the responders was 23%; for the untreated group was 38%; and for the failures was 40% </plain></SENT>
<SENT sid="12" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> survivors achieved a Karnofsky Performance Status (KPS) of &gt; or =90 </plain></SENT>
<SENT sid="13" pm="."><plain>These results indicate that patients with advanced <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> who achieve and remain in remission or a second refractory cytopenia phase with chemotherapy before conditioning can achieve successful long-term remissions following a myeloablative T cell depleted allogeneic HSCT </plain></SENT>
</text></document>